{
    "1": {
        "question": "Lengo kuu la utafiti lilikuwa nini?",
        "options": {
            "A": "Kulinganisha matokeo ya wagonjwa wenye NVAF waliotibiwa na OAC pekee dhidi ya OAC na antiplatelet.",
            "B": "Kupima athari za muda mrefu za OAC kwenye atherosclerosis ya mfumo.",
            "C": "Kuamua ufanisi wa statins katika kupunguza mshtuko wa moyo baada ya kiharusi.",
            "D": "Kutathmini athari za mabadiliko ya mtindo wa maisha kwenye kurudiwa kwa viharusi.",
            "E": "Kuchunguza athari za dawa mpya za anticoagulant kwenye NVAF.",
            "F": "Sijui"
        }
    },
    "2": {
        "question": "Je, uwiano wa hatari kwa vifo vya sababu zote ulikuwa upi wakati wa kutumia OAC + antiplatelet ikilinganishwa na OAC pekee, kulingana na uzito wa uwezekano wa matibabu?",
        "options": {
            "A": "0.63",
            "B": "0.34",
            "C": "1.01",
            "D": "0.48",
            "E": "2.19",
            "F": "Sijui"
        }
    },
    "3": {
        "question": "Ni wakala gani wa antiplatelet uliokuwa ukitolewa mara nyingi zaidi kwa wagonjwa katika kundi la OAC + antiplatelet?",
        "options": {
            "A": "Clopidogrel",
            "B": "Triflusal",
            "C": "Aspirin",
            "D": "Ticlopidine",
            "E": "Cilostazol",
            "F": "Sijui"
        }
    },
    "4": {
        "question": "Ni matokeo gani yalionyesha tofauti kubwa kati ya makundi ya OAC + antiplatelet na OAC pekee, kulingana na uzito wa uwezekano wa matibabu?",
        "options": {
            "A": "Kiharusi cha hemorrhagic",
            "B": "Mshtuko wa moyo",
            "C": "Matukio ya kutokwa na damu",
            "D": "Kutokwa na damu kwenye njia ya utumbo",
            "E": "Kurudiwa kwa kiharusi",
            "F": "Sijui"
        }
    },
    "5": {
        "question": "Ni asilimia gani ya washiriki wa utafiti walikuwa wanaume?",
        "options": {
            "A": "50.0%",
            "B": "64.3%",
            "C": "53.2%",
            "D": "59.3%",
            "E": "68.2%",
            "F": "Sijui"
        }
    },
    "6": {
        "question": "Ni hali gani ya atherosclerotic iliyokuwa ya kawaida zaidi iliyoonekana katika idadi ya watu waliofanyiwa utafiti?",
        "options": {
            "A": "Ugonjwa wa kuzuia mishipa ya pembeni",
            "B": "Atherosclerosis ya ubongo",
            "C": "Ugonjwa wa kuzuia mishipa ya moyo",
            "D": "Atheroma ya upinde wa aorta",
            "E": "Ugonjwa wa mishipa ya carotid",
            "F": "Sijui"
        }
    },
    "7": {
        "question": "Ni mbinu gani ya takwimu iliyotumika kurekebisha tofauti za sifa za msingi kati ya makundi mawili ya matibabu?",
        "options": {
            "A": "Urejeshaji wa mstari",
            "B": "ANOVA",
            "C": "Uzito wa uwezekano wa matibabu",
            "D": "Urejeshaji wa logistic",
            "E": "Jaribio la Chi-square",
            "F": "Sijui"
        }
    },
    "8": {
        "question": "Ni asilimia ngapi ya wagonjwa katika utafiti waliotibiwa na anticoagulants za mdomo za moja kwa moja (DOAC) katika kundi la OAC pekee?",
        "options": {
            "A": "45.0%",
            "B": "96.6%",
            "C": "65.2%",
            "D": "34.8%",
            "E": "55.0%",
            "F": "Sijui"
        }
    },
    "9": {
        "question": "Baada ya kurekebisha sifa za msingi kwa kutumia uzito wa uwezekano wa matibabu, ni kundi gani lilionyesha athari za mwingiliano na mipango ya antithrombotic?",
        "options": {
            "A": "Umri",
            "B": "Jinsia",
            "C": "Stents za ubongo au moyo au shinikizo la damu",
            "D": "Kisukari",
            "E": "Hali ya uvutaji sigara",
            "F": "Sijui"
        }
    },
    "10": {
        "question": "Je, ni asilimia gani ya hatari ya kiharusi cha ischemic kinachorudiwa kwa wagonjwa waliopokea OAC + antiplatelet?",
        "options": {
            "A": "3.1%",
            "B": "8.8%",
            "C": "2.9%",
            "D": "6.1%",
            "E": "11.2%",
            "F": "Sijui"
        }
    },
    "11": {
        "question": "Kulingana na utafiti, ni vipi uwiano wa wagonjwa wenye shinikizo la damu kati ya makundi ya OAC + antiplatelet na OAC ulivyolinganishwa katika uchambuzi usiobadilishwa?",
        "options": {
            "A": "Ina uwezekano mdogo katika kundi la OAC + antiplatelet",
            "B": "Ina uwezekano mkubwa katika kundi la OAC + antiplatelet",
            "C": "Sawa katika makundi yote mawili",
            "D": "Kwa kiasi kikubwa chini katika kundi la OAC",
            "E": "Kwa kiasi kikubwa juu katika kundi la OAC",
            "F": "Sijui"
        }
    },
    "12": {
        "question": "Ni wagonjwa wangapi waliopokea mchanganyiko wa OAC na wakala wa antiplatelet wakati wa kuondoka hospitalini?",
        "options": {
            "A": "296",
            "B": "445",
            "C": "149",
            "D": "103",
            "E": "193",
            "F": "Sijui"
        }
    },
    "13": {
        "question": "Ni sababu gani iliyotambuliwa kama mchangiaji huru wa kutumia OAC + antiplatelet?",
        "options": {
            "A": "Stenosis ya mishipa ya ubongo",
            "B": "Kisukari",
            "C": "Stent ya moyo",
            "D": "Umri",
            "E": "Uvutaji sigara wa sasa",
            "F": "Sijui"
        }
    },
    "14": {
        "question": "Je, umri wa wastani wa washiriki wa utafiti ulikuwa upi?",
        "options": {
            "A": "85",
            "B": "78",
            "C": "70",
            "D": "63",
            "E": "75",
            "F": "Sijui"
        }
    },
    "15": {
        "question": "Ni mchoro gani unaoonyesha kulinganisha kwa mlinganyo wa maisha ya Kaplanâ€“Meier kulingana na mpango wa antithrombotic?",
        "options": {
            "A": "Mchoro 1",
            "B": "Mchoro 2",
            "C": "Mchoro 3",
            "D": "Mchoro 4",
            "E": "Mchoro wa Ziada 1",
            "F": "Sijui"
        }
    },
    "16": {
        "question": "Je, statin ilitolewa mara ngapi wakati wa kuondoka hospitalini katika kundi la utafiti?",
        "options": {
            "A": "50.0%",
            "B": "80.0%",
            "C": "97.3%",
            "D": "90.5%",
            "E": "85.1%",
            "F": "Sijui"
        }
    },
    "17": {
        "question": "Ni asilimia ngapi ya wagonjwa waliotibiwa na DOAC pekee walionekana kupokea dozi isiyotosha?",
        "options": {
            "A": "25.0%",
            "B": "9.0%",
            "C": "10.4%",
            "D": "12.5%",
            "E": "5.0%",
            "F": "Sijui"
        }
    },
    "18": {
        "question": "Katika uchambuzi usiobadilishwa, ni uwiano gani wa hatari uliobainishwa kwa matukio ya kutokwa na damu wakati wa kulinganisha OAC na OAC + antiplatelet?",
        "options": {
            "A": "0.63",
            "B": "5.99",
            "C": "1.12",
            "D": "0.34",
            "E": "2.19",
            "F": "Sijui"
        }
    },
    "19": {
        "question": "Ni vigezo gani vilivyokuwa vya kawaida zaidi kwa wagonjwa waliopokea OAC + antiplatelet dhidi ya OAC pekee?",
        "options": {
            "A": "Kisukari, Dyslipidemia, GFR ya chini",
            "B": "Shinikizo la damu, CAOD, Stents za ubongo na moyo",
            "C": "Umri, Uvutaji sigara, NIHSS ya awali",
            "D": "Uvutaji sigara wa sasa, PAOD, CHF",
            "E": "Jinsia, Atheroma ya aorta, Statin ya dozi kubwa",
            "F": "Sijui"
        }
    },
    "20": {
        "question": "Kulingana na Jedwali 2, ni uwiano gani wa hatari kwa kiharusi cha ischemic wakati wa kutumia OAC + antiplatelet ikilinganishwa na OAC pekee katika makundi yaliyorekebishwa?",
        "options": {
            "A": "0.48",
            "B": "6.12",
            "C": "2.76",
            "D": "1.01",
            "E": "0.34",
            "F": "Sijui"
        }
    }
}